BridgeBio Halting Gene Therapy Development for Genetic Disorders
Tuesday, 10 September 2024, 14:08
BridgeBio Stops Gene Therapy Development for Genetic Disorder
BridgeBio, a notable pharmaceutical company, announced that it will stop the development of its gene therapy targeting a specific genetic disorder. The decision follows disappointing results from early-to-mid stage studies which failed to meet critical thresholds for continued funding.
Key Reasons for Halting Development
- Insufficient Study Results: The therapy did not meet the necessary benchmarks.
- Financial Considerations: The company assessed that further investment was not justifiable.
- Focus Shift: BridgeBio plans to redirect its resources towards more promising avenues in gene therapy.
This development marks a significant shift in BridgeBio's strategic focus within the gene therapy landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.